In this report, we reveal industry predictions for the rare disease landscape in 2034 and explore key approaches that show great promise, including gene therapies, artificial intelligence, whole-genome screening and personalised treatment, before assessing what the top priorities should be over the next decade to improve patient care.
All articles:
Empowering solutions in Medical Affairs
Unlock the full potential of Medical Affairs teams in the pharmaceutical industry to address complex challenges and lead strategic decision-making.
PROs: Can patients ‘co-develop’ their treatment?
Discover the value of patient-reported outcomes (PROs) in clinical trials and how they can help address unmet needs in ovarian cancer.
Harnessing AI to revolutionise clinical trials
Discover how digital twins and synthetic control arms can revolutionise drug development. Learn about their impact on precision medicine and patient outcomes.
How to measure the value of Medical Affairs teams
Discover how to redefine qualitative and quantitative metrics in Medical Affairs to improve patient outcomes whilst demonstrating value to the organisation.
The future of biotechnology: redefining undruggable targets
Martin Guppy shares his views on what the future of drug discovery may look like
San Francisco seeking to be the world’s top biotech cluster
Cambridge in the greater Boston area calls itself the most innovative square mile on the planet but San Francisco’s Bay Area is snapping at it heels
Where is the most innovative square mile on the planet?
How did Kendall Square in Cambridge, Massachusetts become the centre of the world’s largest biotech hub?
Why US biotechs increasingly choose Switzerland for their European HQ
Why a combination of talent, tax, environment and infrastructure makes Switzerland a particularly attractive option for US biotechs.
When is a European Biotech going to match its US counterparts?
Despite the hurdles,there is optimism that a European biotech will emerge as a global marketing success